Michael R. Patrone

• Zuora, Inc. in connection with its pending $1.7 billion sale to Silver Lake and GIC Pte. Ltd.
• MyoKardia, Inc. in connection with its $13.1 billion sale to Bristol-Myers Squibb Company
• Biocon Biologics Limited in connection with its acquisition of Viatris Inc.’s biosimilars business for cash and stock valued at approximately $3.335 billion
• Twilio Inc. in connection with its acquisition of SendGrid, Inc. in an all-stock transaction valued at approximately $3 billion
• Investors in Signal Sciences Corp. in connection with Signal Sciences’ $775 million sale to Fastly, Inc.
• Foundation Medicine, Inc. in connection with its merger with Roche at an enterprise valuation of $5.3 billion
• PTC Inc. in connection with its strategic partnership with Rockwell Automation, Inc. and securing a $1 billion equity investment
• Pear Therapeutics, Inc. in connection with its business combination with SPAC Thimble Point Acquisition Corp. in a transaction valued at approximately $1.6 billion
• Markforged, Inc. in connection with its business combination with SPAC one in a transaction valued at approximately $2.1 billion
• Alpha Healthcare Acquisition Corp. in connection with its business combination with Humacyte, Inc. in a transaction valued at approximately $1.1 billion
• Cano Health, LLC in connection with its business combination with SPAC Jaws Acquisition Corp in a transaction valued at approximately $5.9 billion  
• Existing investors in Billtrust in connection with Billtrust’s business combination with SPAC South Mountain Merger Corporation in a transaction valued at approximately $2.5 billion
• Immatics N.V. in connection with its business combination with SPAC Arya Sciences Acquisition Corp. in a transaction valued at approximately $1 billion
• Investors in connection with Ginkgo Bioworks, Inc.’s business combination with SPAC Soaring Eagle Acquisition Corp. in a transaction valued at approximately $17.5 billion
• Investors in connection with POINT Biopharma Inc.’s business combination with SPAC Therapeutics Acquisition Corp. d/b/a Research Alliance Corp. I in a transaction valued at approximately $924 million
• Evergreen Coast Capital in connection with its $1.6 billion take-private acquisition of Gigamon Inc.*
• Hewlett Packard Enterprise Company in connection with the $7 billion spin-off and merger of its Enterprise Services business with Computer Sciences Corporation to form DXC Technology Company*
• Hologic, Inc. in connection with the sale of its blood screening business for $1.85 billion to Grifols S.A.*
• Diamond Resorts International, Inc. in connection with its $2.2 billion sale to Apollo Management*
• Marriott International, Inc. in its $12.2 billion acquisition of Starwood Hotels & Resorts Worldwide, Inc.*
• Shire plc in connection with its abandoned $54.8 billion sale to AbbVie Inc.*
• Bertelsmann SE & Co. KGaA and Random House in connection with the merger of Random House with Penguin Publishing House*
• Dalian Wanda Group in connection with its $2.6 billion acquisition of AMC Entertainment Holdings, Inc.*

*Denotes experience prior to joining Goodwin.

Michael represents the most sophisticated and well-known asset managers in the world, including top-tier private equity and venture capital funds, hedge funds, family offices and multi-strategy investors, as well as their respective portfolio companies, in acquisitions, sales, and financings.